Pharma BD Deal Intelligence
Watson's ~$1.9B all-cash purchase of Andrx built the third-largest US generics company by prescriptions but forced FTC divestitures across 13 overlapping markets, and a decade-plus later the deal's clearest legacy is Anda—the distribution unit that outlived the rest of the Andrx pipeline and was later sold to Teva for $500M.
A messy, FTC-scarred combination that nonetheless yielded one durable long-term winner (Anda) inside an otherwise unremarkable integration.
Full analysis, sources & comparables →Andrx shares surged 10.65% while Watson shares declined; Standard & Poor's placed Watson's corporate credit rating on negative 'CreditWatch' due to Andrx's FDA…
FTC consent order required divestitures in 13 generic drug markets where Watson and Andrx ANDAs overlapped - a partial drag on the deal's projected synergies.
Watson closed Andrx for ~$1.9B, financed via a $650M term loan; the combined entity became the #3 US generics company by prescriptions with $30M targeted…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Watson Pharmaceuticals acquired Andrx Corporation for approximately $1.9B in cash, financed in part through a $650M term loan, consolidating its US generics position and adding Andrx's difficult-to-replicate controlled-release formulations. The combination created the third-largest US generics company by prescriptions. The FTC required divestitures in 13 overlapping generic drug markets as a condition of closing.
A messy, FTC-scarred combination that nonetheless yielded one durable long-term winner (Anda) inside an otherwise unremarkable integration.
Assessment window: 15yr post-close.
Andrx's commercial value was built on hard-to-replicate controlled-release generics (Cartia XT diltiazem, generic metoprolol succinate, others), plus oral contraceptives and a third-party generics distribution arm. The 'indication' here is really therapeutic-class breadth: cardiovascular, CNS, women's health - all categories where 24-hour controlled-release formulations command pricing closer to brand than commodity immediate-release generics.
By the March 2007 close (this row reflects the close-date entry for the same Watson-Andrx transaction), the US generics consolidation thesis was in full swing. Teva had just absorbed Ivax (2006), Novartis-Sandoz had bought Eon Labs, and Barr was preparing the Pliva merger. Watson, historically oral-contraceptive heavy, gained the ANDA depth and controlled-release manufacturing know-how to compete against Teva, Mylan, and Sandoz on patent-cliff opportunities. C&EN industry coverage noted Lehman Brothers calling the deal 'no surprise' and WR Hambrecht 'applauding' it as a precursor to further generics M&A. The FTC required divestitures across 13 overlapping ANDAs before clearance, slightly thinning the synergy story. Post-close, Watson eventually rebranded as Actavis and continued the rollup that produced today's Allergan/Teva-era US generics structure.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation (this deal) | 2007 | $1.9B | 62 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
← Browse all deals · How we score deals
More: 2007 deals · Watson Pharmaceuticals (Actavis Inc.) deals